Evidence map›Paper›PMID 35843177›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2022

Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study.

Sonia Priou, Guillaume Lamé, Gérard Zalcman, Marie Wislez, Romain Bey, Gilles Chatellier, Jacques Cadranel, Xavier Tannier, Laurent Zelek, Christel Daniel and 3 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. COVID-19 and lung cancer.Pathologica · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Sonia PriouAssistance Publique - Hôpitaux de Paris, Innovation and Data, IT Department, Paris, France; Université Paris-Saclay, CentraleSupélec, Laboratoire Génie Industriel, Gif-sur-Yvette, France.
Guillaume LaméUniversité Paris-Saclay, CentraleSupélec, Laboratoire Génie Industriel, Gif-sur-Yvette, France.
Gérard ZalcmanUniversité de Paris Cité, Assistance Publique - Hôpitaux de Paris, Department of Thoracic Oncology & Centre D'Investigation Clinique INSERM 1425, Bichat University Hospital, Paris, France.
Marie WislezUniversité de Paris Cité, Assistance Publique - Hôpitaux de Paris, Department of Pneumology, Cochin Teaching Hospital, Paris, France.
Romain BeyAssistance Publique - Hôpitaux de Paris, Innovation and Data, IT Department, Paris, France.
Gilles ChatellierUniversité de Paris Cité, Department of Medical Informatics, Assistance Publique Hôpitaux de Paris. Centre-Université de Paris (APHP-CUP), F-75015 Paris, France.
Jacques CadranelSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Pneumologie et Oncologie Thoracique, Hôpital Tenon and GRC04 Theranoscan Sorbonne Université, Paris, France.
Xavier TannierSorbonne Université, Inserm, Université Sorbonne Paris Nord, Laboratoire D'Informatique Médicale et D'Ingénierie des Connaissances pour La e-Santé, LIMICS, Paris, France.
Laurent ZelekUniversité de Seine Saint Denis, Assistance Publique - Hôpitaux de Paris, Department of Thoracic Oncology, Avicenne University Hospital, Paris, France.
Christel DanielAssistance Publique - Hôpitaux de Paris, Innovation and Data, IT Department, Paris, France; Sorbonne Université, Inserm, Université Sorbonne Paris Nord, Laboratoire D'Informatique Médicale et D'Ingénierie des Connaissances pour La e-Santé, LIMICS, Paris, France.
Christophe TournigandUniversité Paris Est Créteil, INSERM, IMRB, Assistance Publique - Hôpitaux de Paris, Department of Medical Oncology, Henri Mondor and Albert Chenevier Teaching Hospital, Créteil, France.
Emmanuelle KempfSorbonne Université, Inserm, Université Sorbonne Paris Nord, Laboratoire D'Informatique Médicale et D'Ingénierie des Connaissances pour La e-Santé, LIMICS, Paris, France; Université Paris Est Créteil, Assistance Publique - Hôpitaux de Paris, Department of Medical Oncology, Henri Mondor and Albert Chenevier Teaching Hospital, Créteil, France. Electronic address: Emmanuelle.kempf@aphp.fr.
Assistance Publique – Hôpitaux de Paris (AP-HP) Cancer Group
Inserm · FRUniversité Paris Cité · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRDélégation Paris 5 · FRSorbonne Université · FRUniversité Sorbonne Paris Nord · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe SARS-CoV-2 pandemic has impacted the care of cancer patients. This study sought to assess the pandemic's impact on the clinical presentations and outcomes of newly referred patients with lung cancer from the Greater Paris area.

methodsWe retrospectively retrieved the electronic health records and administrative data of 11.4 million patients pertaining to Greater Paris University Hospital (AP-HP). We compared indicators for the 2018-2019 period to those of 2020 in regard to newly referred lung cancer cases. We assessed the initial tumour stage, the delay between the first multidisciplinary tumour board (MTB) and anticancer treatment initiation, and 6-month overall survival (OS) rates depending on the anticancer treatment, including surgery, palliative systemic treatment, and best supportive care (BSC).

resultAmong 6240 patients with lung cancer, 2179 (35%) underwent tumour resection, 2069 (33%) systemic anticancer therapy, 775 (12%) BSC, whereas 1217 (20%) did not receive any treatment. During the first lockdown, the rate of new diagnoses decreased by 32% compared with that recorded in 2018-2019. Initial tumour stage, repartition of patients among treatment categories, and MTB-related delays remained unchanged. The 6-month OS rates of patients diagnosed in 2018-2019 who underwent tumour resection were 98% versus 97% (HR = 1.2; 95% CI: 0.7-2.0) for those diagnosed in 2020; the respective rates for patients who underwent systemic anticancer therapy were 78% versus 79% (HR = 1.0; 95% CI: 0.8-1.2); these rates were 20% versus 13% (HR = 1.3; 95% CI: 1.1-1.6) for those who received BSC. COVID-19 was associated with poorer OS rates (HR = 2.1; 95% CI: 1.6-3.0) for patients who received systemic anticancer therapy.

conclusionsThe SARS-CoV-2 pandemic has not exerted any deleterious impact on 6-month OS of new lung cancer patients that underwent active anticancer therapy in Greater Paris University hospitals.

Indexed as

COVID-19Lung NeoplasmsCohort StudiesCommunicable Disease ControlHumansPandemicsPrognosisRetrospective StudiesSARS-CoV-2COVID-19Delivery of health careEarly cancer detectionLung neoplasmsQuality of health careRoutinely collected health data

Identifiers

PMID35843177
PMCPMC9234022
OpenAlexW4283586321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.